1. Academic Validation
  2. Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies

Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies

  • J Med Chem. 2006 May 18;49(10):2898-908. doi: 10.1021/jm0510979.
Tina Morwick 1 Angela Berry Janice Brickwood Mario Cardozo Katrina Catron Molly DeTuri Jonathan Emeigh Carol Homon Matt Hrapchak Stephen Jacober Scott Jakes Paul Kaplita Terence A Kelly John Ksiazek Michel Liuzzi Ronald Magolda Can Mao Daniel Marshall Daniel McNeil Anthony Prokopowicz 3rd Christopher Sarko Erika Scouten Cynthia Sledziona Sanxing Sun Jane Watrous Jiang Ping Wu Charles L Cywin
Affiliations

Affiliation

  • 1 Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06801-0368, USA. tmorwick@rdg.boeringer-ingelheim.com
Abstract

High-throughput screening is routinely employed as a method for the identification of novel hit structures. Large numbers of active compounds are typically procured in this way and must undergo a rigorous validation process. This process is described in detail for a collection of screening hits identified as inhibitors of IkappaB kinase-beta (IKKbeta), a key regulatory Enzyme in the nuclear factor-kappaB (NF-kappaB) pathway. From these studies, a promising hit series was selected. Subsequent lead generation activities included the development of a pharmacophore hypothesis and structure-activity relationship (SAR) for the hit series. This led to the exploration of related scaffolds offering additional opportunities, and the various structural classes were comparatively evaluated for Enzyme inhibition, selectivity, and drug-like properties. A novel lead series of thienopyridines was thereby established, and this series advanced into lead optimization for further development.

Figures
Products
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》